The endocannabinoid system in the regulation of emotions throughout lifespan: a discussion on therapeutic perspectives
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Alterations in emotion regulation processes may form the basis of psychopathologies. The endocannabinoid (eCB) system, composed of endogenous ligands, the enzymatic machinery in charge of their metabolism and the specific metabotropic receptors, has emerged as a major neuromodulatory system critically involved in the control of emotional homeostasis and stress responsiveness. Data from animal models indicate that the eCB system plays a key role in brain development, and is probably involved in the control of emotional states from early developmental stages. The present review summarizes the latest information on the role of the eCB system in emotionality and anxiety-related disorders throughout the lifespan. Putative therapeutic strategies based on the pharmacological modulation of this system will be discussed. Given the fact that the pharmacological modulation of the eCB system has recently arisen as a promising strategy in the management of anxiety and mood disorders, the potential efficacy of this pharmacological approach (i.e. blockers of the catabolic pathway) will be discussed, as well as pharmacological alternatives such as modulators of cannabinoid receptors other than the classical CB1 receptor, or administration of other plant-derived compounds (e.g. cannabidiol).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · cited 1×
“Cannabinoids have been extensively proposed as an efficient tool for the management of mood and anxiety disorders (for review see Bosier et al., 2010; Mangieri and Piomelli, 2007; Pacher et al., 2006).”
MethodThe endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 3×
“Pharmacological and genetic disruption of CB1Rs strongly impaired short-term and long-term extinction in auditory fear-conditioning tests, in the absence of changes in memory acquisition and consolidation processes (Marsicano et al., 2002).”
BackgroundResultThe orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568 · cited 5×
“Notably, spatial and temporal distribution of CB1R expression were investigated using CP55,940 and WIN55,2122, non-selective CB1R/CB2R agonists with an affinity for GPR55 (Henstridge et al., 2009; Lauckner et al., 2008; Oka et al., 2007; Ryberg et al., 2007).”
BackgroundMethodInfluentialIdentification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Brain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373 · cited 2×
“Upon release, 2-AG is mainly hydrolysed by monoglyceride lipase (Dinh et al., 2002), and, to a lesser extent, by a/b-hydrolase 6 and 12 (Blankman et al.”
BackgroundCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 1×
“DAGLs are distributed to the developing axons of pyramidal neurons (Mulder et al., 2008), while in the adult brain DAGLa is mainly localized in dendrites (Katona et al., 2006).”
BackgroundA Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol
Blankman, J. L., Simon, G. M., & Cravatt, B. F. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.11.006 · Cited by 1,177 · cited 2×
“, 2002), and, to a lesser extent, by a/b-hydrolase 6 and 12 (Blankman et al., 2007) (for an update in the field, see Hanus and Mechoulam, 2010).”
BackgroundBisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E.-J., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200305129 · Cited by 1,039 · cited 1×
“Diacylglycerol lipases (DAGLs) are present in the brain during early development, and expression is maintained throughout life (Berghuis et al., 2007; Bisogno et al., 2003).”
BackgroundAgonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878 · cited 2×
“Moreover, CBD may possess agonistic properties at 5-HT1A receptors (Russo et al., 2005), and some CBD-induced behavioural effects have been demonstrated to be mediated by activation of these 5-HT1A receptors (Resstel et al., 2009; Zanelati et al., 2010).”
BackgroundFone, K. C. F., & Porkess, M. V. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.003 · Cited by 864
Mezey, É., Tóth, Z. E., Cortright, D. N., Arzubi, M. K., Krause, J. E., Elde, R., Guo, A., Blumberg, P. M., & Szallasi, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3655 · Cited by 850 · cited 1×
“TRPV1s are expressed in various brain regions related to anxiety (McGaraughty et al., 2003; Mezey et al., 2000), and recently their role in anxiety has been investigated.”
BackgroundFunctional Role of High-Affinity Anandamide Transport, as Revealed by Selective Inhibition
Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A., & Piomelli, D. (1997) · Science · doi:10.1126/science.277.5329.1094 · Cited by 813
Kirkham, T. C., Williams, C. M., Fezza, F., & Marzo, V. D. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704767 · Cited by 788
An endocannabinoid mechanism for stress-induced analgesia
Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Michael Walker, J., Holmes, P. V., Crystal, J. D., et al. (2005) · Nature · doi:10.1038/nature03658 · Cited by 778 · cited 1×
“CB2R expression has been detected in several brain regions (for a review, see Atwood and Mackie, 2010), and its participation in depression and drug addiction processes (Onaivi et al., 2008), as well as in psychotic disorders (Ishiguro et al., 2010) has been recently demonstrated.”
BackgroundCannabinoid Receptors: Where They are and What They do
Mackie, K. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01671.x · Cited by 638
Laviola, G., Macrı̀, S., Morley-Fletcher, S., & Adriani, W. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(03)00006-x · Cited by 621
Self-citationAction of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608
High-potency cannabis and the risk of psychosis
Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.064220 · Cited by 567 · cited 1×
“Evidence from animal studies and recent longitudinal human studies has also suggested a potential association between regular heavy cannabis use during adolescence and psychotic episodes (see Di Forti et al., 2009; Hall and Degenhardt, 2008; Leweke and Koethe, 2008 for review).”
ResultThe neurobiology of social play behavior in rats
Vanderschuren, L. J. M. J., Niesink, R. J. M., & Van Pee, J. M. (1997) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(96)00020-6 · Cited by 559
Molecular Composition of the Endocannabinoid System at Glutamatergic Synapses
Katona, I., Urbán, G. M., Wallace, M., Ledent, C., Jung, K.-M., Piomelli, D., Mackie, K., & Freund, T. F. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0309-06.2006 · Cited by 511
Cannabis and anxiety: a critical review of the evidence
Crippa, J. A., Zuardi, A. W., Martín‐Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar‐Poli, P. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1048 · Cited by 509
Endocannabinoid system and stress and anxiety responses
VIVEROS, M., MARCO, E., & FILE, S. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.029 · Cited by 485
Self-citationPatel, S., Roelke, C. T., Rademacher, D. J., Cullinan, W. E., & Hillard, C. J. (2004) · Endocrinology · doi:10.1210/en.2004-0638 · Cited by 475 · cited 1×
“A single episode of immobilization restraint (30min) reduces hypothalamic 2-AG and AEA contents within amygdala and hippocampus (Gorzalka et al., 2008; Patel et al., 2004, 2005; Rademacher et al., 2008).”
BackgroundNurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., Morlion, B. J., & Haines, D. (2007) · Pain · doi:10.1016/j.pain.2007.08.028 · Cited by 431 · cited 2×
“This innovative drug has been reported to be effective against neuropathic pain (Berman et al., 2004; Nurmikko et al., 2007) and seems to have a promising future in the management of spasticity caused by MS (Collin et al.”
BackgroundFegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078980 · Cited by 427
Antianxiety effect of cannabidiol in the elevated plus-maze
Guimarães, F. S., Chiaretti, T. M., Graeff, F. G., & Zuardi, A. W. (1990) · Psychopharmacology · doi:10.1007/bf02244012 · Cited by 379 · cited 1×
“Systemic CBD administration has been reported to induce anxiolyticlike effects in animal models (Guimaraes et al., 1990; Resstel et al., 2006).”
BackgroundEnhancing Cannabinoid Neurotransmission Augments the Extinction of Conditioned Fear
Chhatwal, J. P., Davis, M., Maguschak, K. A., & Ressler, K. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300655 · Cited by 376
Antidepressant‐like effects of cannabidiol in mice: possible involvement of 5‐HT1Areceptors
Zanelati, T., Biojone, C., Moreira, F., Guimarães, F., & Joca, S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00521.x · Cited by 366
Berman, J. S., Symonds, C., & Birch, R. (2004) · Pain · doi:10.1016/j.pain.2004.09.013 · Cited by 362 · cited 1×
“This innovative drug has been reported to be effective against neuropathic pain (Berman et al., 2004; Nurmikko et al., 2007) and seems to have a promising future in the management of spasticity caused by MS (Collin et al., 2007), and was devoid of undesired side effects related to anxiety.”
BackgroundMarsch, R., Foeller, E., Rammes, G., Bunck, M., Kössl, M., Holsboer, F., Zieglgänsberger, W., Landgraf, R., Lutz, B., & Wotjak, C. T. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3303-06.2007 · Cited by 359
The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02192.x · Cited by 354 · cited 2×
“…among CB1R knock-out mice exposed to paradigms of unconditioned anxiety (i.e. the light–dark box and the elevated plus maze); this altered behavioural phenotype was also accompanied by profound alterations in adrenocortical activity (Haller et al., 2002; Martin et al., 2002; Uriguen et al., 2004).”
BackgroundDe Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G., & Di Marzo, V. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02082-2 · Cited by 347
Laviola, G., Adriani, W., Terranova, M. L., & Gerra, G. (1999) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(99)00032-9 · Cited by 345
Self-citationRisk Taking and Novelty Seeking in Adolescence: Introduction to Part I
KELLEY, A. E., SCHOCHET, T., & LANDRY, C. F. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1308.003 · Cited by 325
Haller, J., Varga, B., Ledent, C., Barna, I., & Freund, T. F. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03293.x · Cited by 284 · cited 1×
“Data from both genetic and pharmacological blockade of CB1Rs are controversial, since conflicting results have also been reported (Haller et al., 2004a, 2004b; Marsicano et al., 2002).”
ResultCannabinoids in Clinical Practice
Williamson, E. M., & Evans, F. J. (2000) · Drugs · doi:10.2165/00003495-200060060-00005 · Cited by 283 · cited 2×
“However, the therapeutic use of cannabinoids can also be accompanied by adverse reactions such as panic or anxiety attacks, which are worse in the elderly and in women, and less likely in children (Croxford 2003; Williamson and Evans, 2000).”
BackgroundResstel, L. B. M., Tavares, R. F., Lisboa, S. F. S., Joca, S. R. L., Corrêa, F. M. A., & Guimarães, F. S. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00046.x · Cited by 283 · cited 4×
“, 2005), and some CBD-induced behavioural effects have been demonstrated to be mediated by activation of these 5-HT1A receptors (Resstel et al., 2009; Zanelati et al., 2010).”
BackgroundInfluentialWindows of vulnerability to psychopathology and therapeutic strategy in the adolescent rodent model
Adriani, W., & Laviola, G. (2004) · Behavioural Pharmacology · doi:10.1097/00008877-200409000-00005 · Cited by 267 · cited 1×
“Among adolescents, affiliative and playful behaviours are prevalent, together with a notable trend for sensation-seeking and risktaking (Adriani and Laviola, 2004; Kelley et al., 2004; La Greca et al., 2001, Laviola et al., 1999; Primus and Kellogg, 1989; Spear, 2000; Vanderschuren et al., 1997).”
BackgroundSelf-citationBrain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects
Onaivi, E. S., Ishiguro, H., Gong, J.-P., Patel, S., Meozzi, P. A., Myers, L., Perchuk, A., Mora, Z., Tagliaferro, P. A., Gardner, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001640 · Cited by 257
Haller, J., Varga, B., Ledent, C., & Freund, T. F. (2004) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000135704.56422.40 · Cited by 241 · cited 1×
“Data from both genetic and pharmacological blockade of CB1Rs are controversial, since conflicting results have also been reported (Haller et al., 2004a, 2004b; Marsicano et al., 2002).”
ResultRademacher, D. J., Meier, S. E., Shi, L., Vanessa Ho, W.-S., Jarrahian, A., & Hillard, C. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.06.012 · Cited by 233 · cited 3×
“A single episode of immobilization restraint (30min) reduces hypothalamic 2-AG and AEA contents within amygdala and hippocampus (Gorzalka et al., 2008; Patel et al., 2004, 2005; Rademacher et al., 2008).”
BackgroundLidow, M. S., Goldman-Rakic, P. S., & Rakic, P. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.10218 · Cited by 232
Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors
Urigüen, L., Pérez-Rial, S., Ledent, C., Palomo, T., & Manzanares, J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.01.003 · Cited by 218 · cited 2×
“…among CB1R knock-out mice exposed to paradigms of unconditioned anxiety (i.e. the light–dark box and the elevated plus maze); this altered behavioural phenotype was also accompanied by profound alterations in adrenocortical activity (Haller et al., 2002; Martin et al., 2002; Uriguen et al., 2004).”
BackgroundCannabis and psychiatric disorders: it is not only addiction
Leweke, F. M., & Koethe, D. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00106.x · Cited by 213 · cited 1×
“Evidence from animal studies and recent longitudinal human studies has also suggested a potential association between regular heavy cannabis use during adolescence and psychotic episodes (see Di Forti et al., 2009; Hall and Degenhardt, 2008; Leweke and Koethe, 2008 for review).”
ResultGorzalka, B. B., Hill, M. N., & Hillard, C. J. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.004 · Cited by 211 · cited 2×
“A single episode of immobilization restraint (30min) reduces hypothalamic 2-AG and AEA contents within amygdala and hippocampus (Gorzalka et al., 2008; Patel et al., 2004, 2005; Rademacher et al., 2008).”
BackgroundMicale, V., Cristino, L., Tamburella, A., Petrosino, S., Leggio, G. M., Drago, F., & Di Marzo, V. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.98 · Cited by 207
Effects of cannabidiol in animal models predictive of antipsychotic activity
Zuardi, A. W., Antunes Rodrigues, J., & Cunha, J. M. (1991) · Psychopharmacology · doi:10.1007/bf02244189 · Cited by 191
Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality
Naidu, P. S., Varvel, S. A., Ahn, K., Cravatt, B. F., Martin, B. R., & Lichtman, A. H. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0689-4 · Cited by 184 · cited 2×
“Surprisingly, the reversible FAAH inhibitor, 1-oxo-1-[5-(2-pyridyl)-2-yl]-7phenylheptane (OL-135) has been mostly tested in painrelated models (Chang et al., 2006; Lichtman et al., 2004), and no anxiety-related effects were observed when evaluated in the elevated plus maze (Naidu et al., 2007).”
BackgroundResstel, L. B. M., Joca, S. R. L., Moreira, F. A., Corrêa, F. M. A., & Guimarães, F. S. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.05.016 · Cited by 182 · cited 1×
“Systemic CBD administration has been reported to induce anxiolyticlike effects in animal models (Guimaraes et al., 1990; Resstel et al., 2006).”
BackgroundPatel, S., Cravatt, B. F., & Hillard, C. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300535 · Cited by 164 · cited 1×
“A single episode of immobilization restraint (30min) reduces hypothalamic 2-AG and AEA contents within amygdala and hippocampus (Gorzalka et al., 2008; Patel et al., 2004, 2005; Rademacher et al., 2008).”
BackgroundPatel, S., & Hillard, C. J. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06266.x · Cited by 162 · cited 1×
“Changes in eCB content in specific brain areas have been reported in response to a number of environmental stimuli (Gorzalka et al., 2008; Patel and Hillard, 2008).”
BackgroundBidirectional cannabinoid modulation of social behavior in adolescent rats
Trezza, V., & Vanderschuren, L. J. M. J. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1025-3 · Cited by 159 · cited 1×
“The direct CB1R agonist WIN55,212-2 reduced social play, whereas the indirect cannabinoid agonist URB597 enhanced this behaviour (Trezza and Vanderschuren, 2008).”
BackgroundInhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms
Chang, L., Luo, L., Palmer, J. A., Sutton, S., Wilson, S. J., Barbier, A. J., Breitenbucher, J. G., Chaplan, S. R., & Webb, M. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706699 · Cited by 155 · cited 2×
“Surprisingly, the reversible FAAH inhibitor, 1-oxo-1-[5-(2-pyridyl)-2-yl]-7phenylheptane (OL-135) has been mostly tested in painrelated models (Chang et al., 2006; Lichtman et al., 2004), and no anxiety-related effects were observed when evaluated in the elevated plus maze (Naidu et al., 2007).”
BackgroundGarcía-Gutiérrez, M. S., & Manzanares, J. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379507 · Cited by 153
Primus, R. J., & Kellogg, C. K. (1989) · Developmental Psychobiology · doi:10.1002/dev.420220608 · Cited by 146
Critical age windows for neurodevelopmental psychiatric disorders: evidence from animal models
Marco, E. M., Macrì, S., & Laviola, G. (2011) · Neurotoxicity Research · doi:10.1007/s12640-010-9205-z · Cited by 144
Self-citationZhang, D., Saraf, A., Kolasa, T., Bhatia, P., Zheng, G. Z., Patel, M., Lannoye, G. S., Richardson, P., Stewart, A., Rogers, J. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.11.009 · Cited by 99
Morozov, Y. M., Torii, M., & Rakic, P. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhp028 · Cited by 94 · cited 2×
“Furthermore, the CB1R protein can be detected in early neural progenitors (Aguado et al., 2005, 2006; Morozov et al., 2009) and in the axons and growth cones of developing cortical projection neurons (Mulder et al.”
Background
Cited by
Stress, glucocorticoids and memory: implications for treating fear-related disorders
de Quervain, D., Schwabe, L., & Roozendaal, B. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.155 · Cited by 484
Campos, A. C., Ferreira, F. R., & Guimarães, F. S. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.012 · Cited by 139
“In addition to serotonin, however, endocannabinoids also play a complex role in the regulation of emotional states (Marco et al., 2011; Marco and Laviola, 2012; Viveros et al., 2005; Hill and Gorzalka, 2004; Hill and Gorzalka, 2006; Campos et al., 2010).”
BackgroundThe maternal deprivation animal model revisited.
Marco, E. M., Llorente, R., López-Gallardo, M., Mela, V., Llorente-Berzal, Á., Prada, C., & Viveros, M.-P. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.01.015 · Cited by 132
Self-citationGage, S. H., Hickman, M., Heron, J., Munafò, M. R., Lewis, G., Macleod, J., & Zammit, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122896 · Cited by 90
“[5] The cannabinoid system in the brain has been implicated in emotional regulation,[6] but biological mechanisms that might underlie the association between cannabis use and depression are not known, and indeed effects of cannabis may differ between the short and long term.”
BackgroundShollenbarger, S. G., Price, J., Wieser, J., & Lisdahl, K. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.03.024 · Cited by 64
Metadata
- Authors
- Marco, E. M., & Laviola, G.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2011-06-21
- Volume
- 26
- Issue
- 1
- Pages
- 150-163
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1974113007
- Cited by
- 65
- References
- 59
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.